Peptide Update: What the FDA Plan Means
By the Peptide Science Desk Editorial TeamFact-checked against FDA and official sources · Not yet reviewed by a licensed clinician. How we check facts
1. The FDA plan is still under review
The government listing still says "pending review." The White House budget office got the FDA plan, called "Interim Access Policy for Compounding Using Certain Peptides," on October 14, 2026. See the listing. It gives no details.
Reuters reported on October 15 that the FDA sent the plan. Reuters also said Hims & Hers has said it plans to offer peptides if the rules allow. (Reuters)
2. What "enforcement discretion" means
News reports say the plan would use "enforcement discretion." In plain words: the FDA would choose not to go after pharmacies that make certain peptides. A medical spa trade group explains that the peptides would still be unapproved drugs. (AmSpa, Oct 16)
A law firm that advises pharmacies notes the listing does not say when the FDA will issue the plan or what the final version will say. (Buchanan Ingersoll & Rooney, Oct 16)
3. Fact check: is BPC-157 still on the FDA "risky" list?
No. Many posts online still say it is. We checked the FDA page today. In April 2026, BPC-157, TB-500, and 15 other items were moved off the FDA's "Category 2" list because the groups that asked for them took back their request. That does not make them safe or approved. For regular pharmacies, only one peptide is still on the list: kisspeptin-10. See the full list.
4. People report harm
KFF Health News (October 13) talked with people who say they were hurt after taking BPC-157 and the "Wolverine Stack." It also points to FDA reports, like a 36-year-old woman who went to the hospital after taking BPC-157. These reports cannot prove the peptide caused the harm. (KFF Health News)
New simple guides
- FDA Category 2 peptide list: who is on it now?
- What is the "Wolverine Stack"?
- Emideltide (DSIP): the sleep peptide FDA advisers turned down
- Was the FDA peptide ban lifted?